Cite

    James S McCarthy et al.. “Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.” Lancet infectious diseases, vol. 21, no. 12, 2021, pp. 1713–1724. http://access.bl.uk/ark:/81055/vdc_100146357915.0x000024